Company Overview: Abeona

Industry News

3 Jan

Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease

NEW YORK, NY and CLEVELAND, OH –(Marketwired – January 03, 2017) – Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona’s...

Read more

15 Nov

Abeona Therapeutics to Present at World Orphan and Drug Congress Europe 2016

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 15, 2016) – Abeona Therapeutics Inc. (ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, PhD, presenting and VP of Patient Advocacy, Michelle Berg, moderating a panel...

Read more

3 Nov

Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 03, 2016) – Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D. will be presenting, and joining the Clinical Progress of Gene Therapy...

Read more

2 Nov

Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

NEW YORK, NY and CLEVELAND, OH–(Marketwired – November 02, 2016) – Abeona Therapeutics Inc. (ABEO): EB-101 Phase 1 clinical trial therapy demonstrated clinical efficacy of 67% healed wounds at 6 month post-treatment, lasting through 12 months, including collagen biomarker expression EB-101 was well tolerated in patients with recessive dystrophic...

Read more

18 Oct

Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A

NEW YORK, NY, and CLEVELAND, OH–(Marketwired – October 18, 2016) – Abeona Therapeutics Inc. (ABEO), a clinical- stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona’s...

Read more

14 Oct

Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK

NEW YORK, NY and CLEVELAND, OH–(Marketwired – October 14, 2016) – Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that top-line results of the low-dose cohort for ABO-102 in Phase 1/2 clinical trial for Sanfilippo type A (MPS...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address